Seroatlas · Human Serome Atlas

CSAG2

Chondrosarcoma-associated gene 2/3 protein

Also known as: CSAG2_HUMAN, CSAG3, CSAG3A

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9Y5P2
Gene
CSAG2
Ensembl
ENSG00000268916
Chromosome
X
Canonical length
127 aa
Protein class
Predicted intracellular proteins

OverviewNCBI Gene

Predicted to be involved in response to xenobiotic stimulus. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

127 residues, UniProt reviewed canonical sequence.

>Q9Y5P2|CSAG2
     1  MWMGLIQLVE GVKRKDQGFL EKEFYHKTNI KMRCEFLACW PAFTVLGEAW RDQVDWSRLL
    61  RDAGLVKMSR KPRASSPLSN NHPPTPKRRG SGRHPLNPGP EALSKFPRQP GREKGPIKEV
   121  PGTKGSP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CSAG2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Unknown
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.63
Highest tissue expression
3.9 nTPM

Expression across tissuesHPA

Tissue

  • testis: 3.9 nTPM
  • spleen: 2.1 nTPM
  • lymph node: 1.2 nTPM
  • skin: 0.9 nTPM
  • prostate: 0.5 nTPM
  • midbrain: 0.4 nTPM

Single-cell type

  • early primary spermatocytes: 2.6 nCPM
  • undifferentiated spermatogonia: 0.9 nCPM
  • differentiating spermatogonia: 0.6 nCPM
  • basal prostatic cells: 0.3 nCPM
  • prostatic club cells: 0.3 nCPM
  • prostatic hillock cells: 0.3 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • basal ganglia: 0.8 nTPM
  • cerebral cortex: 0.8 nTPM
  • medulla oblongata: 0.7 nTPM
  • pons: 0.7 nTPM
  • white matter: 0.7 nTPM
  • amygdala: 0.6 nTPM

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CSAG2 as an antibody target. Whether an autoantibody or antibody against CSAG2 could matter depends on whether native CSAG2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CSAG2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label CSAG2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/CSAG2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...